MARY HIGH: Open Payments
NPI 1457350019 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,673 in 93 payments from 16 companies in 2025. Trend: 2023 $1,532 · 2024 $1,847 · 2025 $1,673
Food & beverage: $1,673
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $360 |
| Lilly USA, LLC | 10 | $184 |
| GlaxoSmithKline, LLC. | 11 | $183 |
| Astellas Pharma US Inc | 12 | $175 |
| AstraZeneca Pharmaceuticals LP | 8 | $166 |
| ABBVIE INC. | 9 | $150 |
| Abbott Laboratories | 8 | $142 |
| Exact Sciences Corporation | 3 | $57 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $50 |
| PFIZER INC. | 2 | $50 |
Products named: Veozah, TRELEGY ELLIPTA, FREESTYLE LIBRE 3, JARDIANCE, Rybelsus, MOUNJARO, Ozempic, FARXIGA.
Industry payments across DE — which companies pay providers there.
